Hi everyone just popping in for a quick update. It's been a busy year. We published three manuscripts and a fourth that is in preprint and peer review.
Most importantly Cyclarity is now a clinical stage company. We have submitted the trial protocol, investigator’s brochure, CMC package and all materials necessary for authorization to proceed to trials in Australia. Our application is well along in the review and revision process and we expect approval shortly.
Our trial will be co-directed by Dr. Stephen Nicholls and the Victorian Heart Institute – a world leader in CVD drug development. The Nicholls REVERSAL trial helped elevate Lipitor in the early 2000s; the CLEAR Outcomes trial established bempedoic acid as a statin alternative in the 2020s; and they just completed a trial evaluating a drug for the highly anticipated Lp(a) target. This clinical threshold is an enormous milestone for us, and our thanks go out to the team and collaborators.
We are still raising a little bit of money to fund the trial, so contact me if that is an option for you while the value is still low!
Our new papers:
Selective Removal of 7KC by a Novel Atherosclerosis Therapeutic Candidate Reverts Foam Cells to a Macrophage-like Phenotype
https://www.biorxiv....563623.full.pdf
Unraveling the molecular dynamics of sugammadex-rocuronium complexation: a blueprint for cyclodextrin drug design
https://www.sciencedirect.com/science/article/pii/S0144861724002443
Cyclodextrins: Establishing building blocks for AI-driven drug design by determining affinity constants in silico
https://www.sciencedirect.com/science/article/pii/S2001037024000345
Addressing the complexities in measuring cyclodextrin-sterol binding constants: A multidimensional study
https://www.sciencedirect.com/science/article/pii/S0144861723008251
